Showing 3031-3040 of 4079 results for "".
- Study: GLP-1 Linked with PASI Reductionshttps://practicaldermatology.com/news/early-evidence-links-glp-1-therapy-to-pasi-reductions/2486929/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are gaining attention as a potential adjunctive therapy in psoriasis, according to a new review from the National Psoriasis Foundation Medical Board published in JAMA Dermatol
- CKD Linked to Higher Complication Risk After Mohs Surgeryhttps://practicaldermatology.com/news/ckd-linked-to-higher-complication-risk-after-mohs-surgery/2486676/Chronic kidney disease (CKD) was associated with increased postoperative complications following Mohs micrographic surgery (MMS), according to results of a study published as a Research Letter in the Journal of Drugs in Dermatology Authors evaluated
- Meta-Analysis: Similar AK Clearance With PDT and Cryotherapyhttps://practicaldermatology.com/news/meta-analysis-finds-similar-ak-clearance-with-pdt-and-cryotherapy/2486675/A recent systematic review and meta-analysis suggested comparable efficacy and safety of photodynamic therapy (PDT) and cryotherapy for lesion clearence in actinic keratosis (AK). The analysis, published in the Journal of
- AI Dermatology Tools Improve Patient Diagnostic Accuracy in Survey Studyhttps://practicaldermatology.com/news/ai-dermatology-tools-improve-patient-diagnostic-accuracy-in-survey-study/2486637/An AI-powered dermatology application was associated with improved consumer understanding of skin conditions, according to new research published in JAMA Dermatology. The study includ
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://practicaldermatology.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed